Skip to main contentAI and Advanced
/
HESTERBIO · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
HE
NSE · Equity shares · Biotechnology & Drugs35.90 · 1.65%
Hester Biosciences HESTERBIO
NSE:INR 2,207.7
BSE:INR 2,214
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for HESTERBIO
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,171.8
Day rangeINR 2,130 — INR 2,305
52-week rangeINR 1,239.3 — INR 2,683.6
Volume4,565
Market cap2,111.97
P/E23.53
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)332.6
Net Income (INR Cr)55.64
Rev Growth (5 Year %)9.19
EPS Growth (5 Year %)10.07
P/E Ratio23.53
Book Value412.04
EPS65.59
Price/BV5.36Computed
Research path: Interpret Hester Biosciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
HESTERBIOHester Biosciences1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 677.94 | 653.39 | 662.35 |
| Accumulated Depreciation Total | -173.35 | -156.1 | -140.69 |
| Other Liabilities Total | 52.59 | 56.77 | 59.17 |
| Accrued Expenses | 13.87 | 7.39 | 1.11 |
| Long Term Debt | 89.96 | 133.37 | 181.77 |
| Common Stock Total | 8.51 | 8.51 | 8.51 |
| Other Equity Total | 1.38 | 3.67 | 3.21 |
| Other Current Assets Total | 16.24 | 14.89 | 15.99 |
| Prepaid Expenses | 1.1 | 1.68 | 1.27 |
| Total Assets | 677.94 | 653.39 | 662.35 |
| Current Portof LT Debt/Capital Leases | 74.23 | 44.83 | 25.92 |
| Additional Paid-In Capital | 17.51 | 17.51 | 17.51 |
| Cash | 2.77 | 5.59 | 12.31 |
| Total Equity | 360.24 | 314.26 | 291.79 |
| Long Term Investments | 42.58 | 34.05 | 29.93 |
| Retained Earnings(Accumulated Deficit) | 332.84 | 284.57 | 262.57 |
| Total Common Shares Outstanding | 0.85 | 0.85 | 0.85 |
| Property/Plant/Equipment Total-Gross | 584.41 | 565.46 | 548.27 |
| Tangible Book Valueper Share Common Eq | 412.04 | 361.59 | 338.39 |
| Total Liabilities | 317.71 | 339.13 | 370.55 |
| Total Debt | 194.79 | 213.25 | 244.38 |
| Cashand Short Term Investments | 2.77 | 5.59 | 12.31 |
| Total Receivables Net | 111.93 | 96.51 | 102.72 |
| Notes Payable/Short Term Debt | 24.29 | 29.58 | 31.35 |
| Deferred Income Tax | 8.81 | 5.93 | 7.41 |
| Accounts Receivable-Trade Net | 99.55 | 77.83 | 82.08 |
| Property/Plant/Equipment Total-Net | 411.06 | 409.35 | 407.58 |
| Minority Interest | 7.55 | 12.4 | 11.08 |
| Total Current Liabilities | 152.48 | 125.18 | 105.79 |
| Total Inventory | 76.52 | 76.51 | 82.34 |
| Accounts Payable | 24.68 | 29.42 | 26.44 |
| Other Currentliabilities Total | 15.41 | 13.97 | 20.97 |
| Total Long Term Debt | 96.28 | 138.84 | 187.11 |
| Intangibles Net | 9.72 | 6.66 | 3.93 |
| Other Long Term Assets Total | 2.19 | 5.58 | 3.79 |
| Note Receivable-Long Term | 3.83 | 2.57 | 2.5 |
| Total Current Assets | 208.56 | 195.17 | 214.62 |
| Capital Lease Obligations | 6.31 | 5.48 | 5.34 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.64
Price to Sale Ratio6.35
Growth
Debt 5Yr CAGR %13.26
Margins
Operating Margin 12m20.38
Operating Margin 5y Avg15.65
Net Profit Margin 12m17.28
Net Profit Margin 5y12.07
Yield
Dividend Yield %0.45
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk49.04
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,934.8 | 4.64 L | 38.87 | — |
| Divi's Laboratories | INR 7,363.25 | 1.95 L | 74.03 | — |
| Torrent Pharmaceuticals | INR 4,981 | 1.69 L | 76.43 | — |
| Cipla | INR 1,408.25 | 1.14 L | 28.01 | — |
| Zydus Lifesciences | INR 1,121.95 | 1.12 L | 21.29 | — |
Shareholding
Ownership
- Promoter
- 53.73%
- FII
- 0.31%
- MF
- 0.03%
- Other
- 45.96%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Hester Biosciences corrects Executive Director salary to INR 10 lakh - scanx.tradeMarket news · 8 Jul 2026, 12:45 pm
Hester Biosciences corrects Executive Director salary to INR 10 lakh scanx.trade
Hester Biosciences Ltd Quality Grade Downgrade Highlights Mixed Business Fundamentals - MarketsMojoMarket news · 4 Jul 2026, 2:16 am
Hester Biosciences Ltd Quality Grade Downgrade Highlights Mixed Business Fundamentals MarketsMojo
Hester Biosciences Ltd is Rated Hold - MarketsMojoMarket news · 1 Jul 2026, 10:12 am
Hester Biosciences Ltd is Rated Hold MarketsMojo
Hester Biosciences Limited Actuals & Estimates (NSE:HESTERBIO) - TradingViewMarket news · 27 Jun 2026, 2:21 am
Hester Biosciences Limited Actuals & Estimates (NSE:HESTERBIO) TradingView
Hester Biosciences FY26 PAT Doubles to ₹57.4 Cr; Debt-to-Equity Drops to 0.19x - Trade BrainsMarket news · 23 Jun 2026, 1:39 pm
Hester Biosciences FY26 PAT Doubles to ₹57.4 Cr; Debt-to-Equity Drops to 0.19x Trade Brains
Hester Biosciences reports BRSR for FY26 with zero safety incidents - scanx.tradeMarket news · 18 Jun 2026, 3:33 pm
Hester Biosciences reports BRSR for FY26 with zero safety incidents scanx.trade
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.11.0000 per share(110%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.7.0000 per share(70%)Final Dividend
Rusaka Markets Community
Discussion and sentiment for Hester Biosciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Hester Biosciences Limited is an India-based animal healthcare company. The Company is principally engaged in manufacturing poultry vaccines, large animal vaccines, and trading poultry, large animal, and petcare health products. Its segments include Poultry Healthcare, Animal Healthcare, and Others. The Poultry Healthcare vaccines include Gumboro I, Inactivated Chick ND, Inactivated Coryza, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IBD, among others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, PPR Vaccine - Sungri/96, among others. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet, Pawfresh, Synoton, Petsglow, Vitacoat, WormPeril, Hestaliv, TumOnzym and Safeline Spot. Its manufacturing facility is located at Village Meda-Adraj, Taluka Kadi, Mehsana District, Gujarat.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- HESTERBIO
- BSE Code
- 524669
Questions
Stock FAQ
What is the symbol and ISIN of Hester Biosciences?
Hester Biosciences has the symbol HESTERBIO and ISIN - INE782E01017.
What is the current price of Hester Biosciences?
Hester Biosciences is currently trading at INR 2,207.70.
What are the year high and year low of Hester Biosciences?
Hester Biosciences has a year high of INR 2,683.60 and a year low of INR 1,239.30.
What is the market capitalization of Hester Biosciences?
Hester Biosciences has a market capitalization of INR 2,111.97 crore.
What is the P/E ratio of Hester Biosciences?
Hester Biosciences has a P/E ratio of 23.53.
What is the dividend yield of Hester Biosciences?
Hester Biosciences has a dividend yield of 0.45%.
How is the financial performance of Hester Biosciences based on revenue, net income, and EPS?
Hester Biosciences has revenue of INR 332.60 crore, net income of INR 55.64 crore, and EPS of INR 53.51.
What is the book value of Hester Biosciences?
Hester Biosciences has a book value of INR 412.04.
What is the debt-to-equity ratio of Hester Biosciences?
Hester Biosciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Hester Biosciences?
Hester Biosciences has a price-to-book ratio of 5.36 and a price-to-sales ratio of 6.35.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.